GATC Biotech and LifeCodexx Develop a Diagnostic Test for Early Detection of Preeclampsia
Project is funded with 500,000 Euros from the BMBF
"Currently there is no reliable method to predict preeclampsia. This new genetic test will therefore provide additional assurance early in pregnancy," said Dr. Wera Hofmann, Medical Director of LifeCodexx AG.
"We will immediately investigate the new PacBio RS technology for use in the test protocol. This sequencing system of the Third Generation can analyze single molecules in real-time within minutes. Costs and duration of the diagnostic test could be drastically reduced,” added Peter Pohl, CEO of GATC Biotech and chairman of LifeCodexx.
“We are pleased to have a second diagnostic test in our development pipeline, in addition to the non-invasive prenatal diagnostic test for the determination of trisomy 21. It is another step forward towards our goal to become a leader in the field of Next Generation Molecular Diagnostics,” said Dr. Michael Lutz, CEO of LifeCodexx AG.
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.